Chapter

The Biopharmaceutical Cluster in Oxford

Neill Proudfoot

in Changing Governance of Local Economies

Published in print February 2004 | ISBN: 9780199259403
Published online February 2006 | e-ISBN: 9780191603020 | DOI: http://dx.doi.org/10.1093/0199259402.003.0015
 The Biopharmaceutical Cluster in Oxford

Show Summary Details

Preview

This chapter examines two hypotheses on the biopharmaceutical cluster in Oxford. First, that dedicated pharmaceutical firms can be expected to co-locate where they can reduce transaction costs in the market for ideas, where they can exploit untraded localized knowledge externalities, and/or where they can economize on start-up costs. Second, that pure market mechanisms provide inadequate investment in start-up resources because information asymmetries that encourage entrepreneurship will discourage investors. The findings for Oxford are compared to the governance of local collective competition goods in other established or embryonic clusters of biopharmaceutical activity in the UK.

Keywords: Oxford; biopharmaceutical cluster; LCCGs; pharmaceutical firms; industrial policy

Chapter.  10065 words.  Illustrated.

Subjects: International Economics

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.